PMID- 37712561
OWN - NLM
STAT- Publisher
LR  - 20231024
IS  - 1473-6322 (Electronic)
IS  - 1473-6322 (Linking)
VI  - 23
IP  - 6
DP  - 2023 Dec 1
TI  - Effects of allergen immunotherapy on follicular regulatory T cells.
PG  - 507-513
LID - 10.1097/ACI.0000000000000944 [doi]
AB  - PURPOSE OF REVIEW: Emerging evidence indicating that the dysfunction of T 
      follicular regulatory (T FR ) cells contributes to excessive immunoglobulin E 
      (IgE) production and the development of allergic diseases. Conversely, allergen 
      immunotherapy (AIT) modulates T FR cells abundance and function to promote immune 
      tolerance. This review focus on the role of T FR cells in allergic diseases and 
      AIT, with the objective of providing novel insights into the mechanisms 
      underlying immune tolerance of AIT and proposing the potential targeting of T FR 
      cells in the context of allergic diseases. RECENT FINDINGS: Numerous studies have 
      consistently demonstrated that T FR cells play a pivotal role in the inhibition 
      of class switch recombination to IgE in both humans and specific murine models. 
      This suppression is attributed to the actions of neuritin and IL-10 secreted by T 
      FR cells, which exert direct and indirect effects on B cells. In patients with 
      allergic rhinitis, reduced frequencies of circulating or tonsillar T FR cells 
      have been reported, along with impaired functionality in suppressing IgE 
      production. AIT, whether administered subcutaneously or sublingually, reinstates 
      the frequency and functionality of T FR cells in allergic rhinitis patients, 
      accompanied by changes of the chromatin accessibility of T FR cells. The increase 
      in T FR cell frequency following AIT is associated with the amelioration of 
      clinical symptoms. SUMMARY: T FR cells exert an inhibitory effect on IgE 
      production and demonstrate a correlation with the clinical efficacy of AIT in 
      patients with allergic rhinitis, suggesting T FR cells hold promise as a 
      therapeutic target for allergic diseases and potential biomarker for AIT.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Sun, Shi-Ran
AU  - Sun SR
AD  - Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology.
FAU - Yao, Yin
AU  - Yao Y
AD  - Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology.
AD  - Hubei Clinical Research Center for Nasal Inflammatory Diseases.
AD  - Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical 
      College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Liu, Zheng
AU  - Liu Z
AD  - Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji 
      Medical College, Huazhong University of Science and Technology.
AD  - Hubei Clinical Research Center for Nasal Inflammatory Diseases.
AD  - Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical 
      College, Huazhong University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
DEP - 20230915
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
SB  - IM
EDAT- 2023/09/15 12:43
MHDA- 2023/09/15 12:43
CRDT- 2023/09/15 07:43
PHST- 2023/09/15 12:43 [pubmed]
PHST- 2023/09/15 12:43 [medline]
PHST- 2023/09/15 07:43 [entrez]
AID - 00130832-990000000-00084 [pii]
AID - 10.1097/ACI.0000000000000944 [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2023 Dec 1;23(6):507-513. doi: 
      10.1097/ACI.0000000000000944. Epub 2023 Sep 15.